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Diverging Trends in Colorectal Cancer Morbidity 
and Mortal.ity. Earlier Diagnosis Comes at a Price 
L. Bonneux, J. J. Barendregt, C.W.N. Looman and P. J. van der Maas 
In developed countries, time trends in the incidence of colorectal cancer differ markedly from trends in mortality. 
This study sought to explain simultaneously changes in both colorectal cancer incidence and mortality. Data on 
first admissions, interventions and outcome from the national hospital registry over the period 197W989 and 
data on mortality from Statistics Netherlands over the same period were analysed by age-period models and 
subsequently entered in a Markov chain model, simulating disease history from first admission to death. Over the 
period 197b1989, age adjusted numbers of first admissions and interventions increased by 37% and 32%, 
respectively, while mortality declined by 8%. For every 100 patients admitted between 1987 and 1989,13 more 
will survive compared with 1978-1980. Of these, 3 will be saved by improving results of primary treatment but the 
other 10 will survive their diagnosis for the subsequent 10 years. Although progress in treatment has been made, 
therapeutic improvement can account only for the smaller part of the divergence between morbidity and mortality. 
Increased diagnostic activity, raising incidence and lowering mortality simultaneously, is the most likely cause of 
the unexplained divergence. 
Key words: colorectal neoplasms, epidemiology, The Netherlands, prognosis, screen&g, prevention and control, 
computer simulation models 
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INTRODUCTION 
Cancer registers in many developed countries detect increasing 
incidences of cancers unrelated to smoking, and commonly 
attribute these increases to changing environmental hazards 
{ 1,2]. However, in the same countries, trends in cancer mor- 
tality differ strikingly from trends in incidence; as a rule, 
mortality has been decreasing while incidence has been increas- 
ing [3, 41. This divergence between incidence and mortality can 
be explained by improved therapy and/or decreasing lethality 
[ 1, 21. Advances have been made in specific therapies, such as 
the dramatic improvements of treatment in juvenile cancers, and 
the more modest gains realised by adjuvant chemotherapy in 
advanced breast and colorectal cancer [5, 61. However, unspec- 
tacular but effective non-specific hanges have probably contrib- 
uted even more to lowered cancer lethality, because they apply 
to the majority of solid tumours, and such changes include 
better preparation of the surgical patients, safer procedures 
and anaesthesia, improved control of infections, more effective 
reanimation, etc. 
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An alternative hypothesis explaining this divergence is 
increased case detection. By lowering diagnostic thresholds, 
lesions with less invasive potential are added, increasing inci- 
dence and improving prognosis at the same time [7]. If this is 
the case, it implies that part of the observed morbidity increase 
is iatrogenic and perhaps preventable. To shed light on the 
likelihood of either explanation, we have examined the inci- 
dence, mortality and survival from colorectal cancer in The 
Netherlands. 
Colorectal cancer is the second most frequent cancer among 
men and women in The Netherlands, showing an incidence 
increase relative to mortality (Figure 1). 
In The Netherlands, mass screening for colorectal cancer is 
not recommended. The Dutch policy makers feel that the 
unavoidable increase in morbidity and costs, induced by the 
many false positives (faecal occult blood testing) and/or by more 
demanding diagnostic procedures (sigmoido- or colonoscopy) 
are not justified by the still uncertain decrease inmortality [8, 91. 
However, individual physicians may feel otherwise, and are free 
to act accordingly. Long before mass screening for breast cancer 
was introduced in The Netherlands, the regional cancer egistry 
showed increasing numbers of small turnours, witnessing earlier 
diagnosis [lo]. Contrary to breast cancer, we do not possess 
accurate data on colorectal cancer stages at primary diagnosis in 
The Netherlands. Such information would be much harder to 
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Fii 1. Solid lines aad symbols show the age standardised rates (30-64 years) of first admissions, major interventions and deaths within 
The Netherlands. Broken lines and open symbols show the cancer incidence and mortality from the Southeastern Netherlands (1978-1987) 
and the national cancer incidence (1989) [14]. The error bars show 95% confidence limits (see text). 
interpret in any case because staging in colorectal cancer is more 
dependent on modern diagnostic imaging. This may give rise to 
stage migration: previously missed invasion of deeper tissues 
may be diagnosed by more modem diagnostic imaging, such 
as magnetic resonance imaging (MRI), causing an artefactual 
migration from milder to more severe disease stages [ 111. 
This paper presents the trends in !irst admissions for colorectal 
cancer as primary diagnosis, major interventions during these 
first admissions to the hospital and mortality over the period 
19711989 in The Netherlands. The change in prognosis needed 
to explain the divergence between incidence and mortality is 
quantified, and we conclude that it is unlikely that improved 
therapy can explain the improving prognosis. 
PATIENTS AND METHODS 
Numbers of deaths from colon and rectum cancer 
(International Classification of Diseases, 9th revision, Nos 153 
and 154) by calendar year (1978-1989), 5year age group (30-64) 
and sex were obtained from Stcltistics Netherlands [ 121. Person 
years at risk were approximated by the midyear population of an 
age and sex group in a calendar year. Summary estimates over 
age were calculated by using direct standardisation, using the 
European Standard Population as weights; standard errors were 
calculated from the formula: 
where 0 represents the numbers, N the midyear population, w 
the weights and a the 5 year age groups between 30 and 64 years 
[ 131. Colon and rectum cancer were taken together in one group 
to avoid possible changes in codification [3]. Nationwide data on 
colorectal cancer incidence have been available since 1989 [141. 
The regional cancer register in the Southeastern Netherlands 
(SE-N) has published cancer incidences since 1975, but the 
population covered is relatively small (1 million) and, in the 
period of interest (1978-1989), the colorectal cancer mortality in 
SE-N was significantly higher than in the rest of The Netherlands 
(see Figure 1 and Table 1) [IS, 161. 
Therefore, we used primarily national hospital register data 
as a proxy for incidence. In addition to administrative data, the 
hospital register ecords the diagnosis at discharge (primary and 
secondary), the result at discharge (alive or dead), all major 
interventions, and whether it is a first admisison for the con- 
sidered cancer or not. We considered first admissions with 
colorectal cancer as primary diagnosis (International Classifi- 
cation of Diseases, 9th revision, Nos 153 and 154), and major 
interventions during first admission as partial or total colectomy, 
rectum amputation or enterostomy [17]. Comparing the 
(national) incidence for 1989 with the first admissions of the 
hospital register, we decided to limit the analysis up to the age 
of 64 years. The hospital register became increasingly incomplete 
in the higher age groups, but for the younger age groups the 
incidence corresponded closely with the first admissions (see 
Figure 1 and Table 1). It has been shown before that more than 
97% of all patients under 65 years with colorectal cancer are 
treated in The Netherlands [18]. Therefore, the nationwide 
hospital register of The Netherlands is an acceptable proxy of 
colorectal cancer incidence, if limited to the young and middle 
aged patients (30-64 years old). 
Period trends in intervention, first admission and mortality 
rates have been estimated by loglinear regression analysis [ 191. 
The observed rates are related to age group, sex and calendar 
year as follows: 
E,, = N~,p’““,s + Pa,*) 
where E is the expected number (of deaths, first admissions or 
interventions) and N the midyear population; a denotes 5 year 
age groups from 30 to 64 years of age, s sex and x is the calendar 
year. p is the slope of the regression line of the logarithm of the 
rates of every age and sex group versus calendar year, and 
represents the trend of age- and sex-specific rates over time. 
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Table 1. Age standardised incidence and mortality per 100 000 per year and their standard errors 
(SE), by sex, period and source. The cancer registerjiguresfiom the period 19711987 arejhm the 
Southeastern region only; thosejim 1989 are the first available national data (see text) 
Men (30-64 years of age) 
Cancer egister Hospital register 
Incidence Mortality Ratio First Mortality Ratio 
GE) (SE) (SE) admission (SE) (SE) 
(SE) 
1978-1982 34.9 (1.3): 17.9 (l.o)* 1.95 (0.14)* 28.2 (0.3) 14.9 (0.2) 1.90 (0.03) 
198%1987 42.0 (1.9)* 19.2 (1.3): 2.19 (0.18)* 33.9 (0.4) 15.3 (0.3) 2.21 (0.05) 
1989 37.3 (1.0) 15.1 (0.6) 2.47 (0.12) 35.9 (1.0) 15.1 (0.6) 2.38 (0.12) 
Women (30-64 years of age) 
Cancer register Hospital register 
Incidence Mortality Ratio First Mortality Ratio 
(SE) (SE) (SE) admission (SE) (SE) 
(SE) 
19711982 34.7 (1.3)’ 17.6 (l.l)* 1.98 (0.15)* 27.8 (0.3) 14.4 (0.2) 1.93 (0.03) 
1983-1987 35.8 (1.7)* 15.2 (1.1)’ 2.35 (0.21)* 30.2 (0.4) 14.2 (0.3) 2.14 (0.05) 
1989 31.8 (0.9) 13.2 (0.6) 2.41 (0.12) 31.2 (0.8) 13.2 (0.9) 2.36 (0.17) 
* From the Southeastern region; all other data re national. 
Summary estimates over age are calculated by specifying only 
sex as an explanatory p variable. 
The disease history is modelled by a Markov type state 
transition model (see Figure 2). The model assumes three groups 
of patients after definite diagnosis: a fraction which dies during 
first admission termed CFR (case fatality rate); a fraction which 
leaves hospital “cured” and a fraction which will die of the 
disease at some later time, provided they do not die from other 
causes (termed “not cured”). The probability of dying from 
0 Event -_ Transition 
-I Exit through disease specific death 
IDeath] --j-j Other Exit through other causes mortality 
Fii 2. The Markov model1 of colorectal cancer. Incidence is 
determined by age and sex. Persons may die in hospital (CFR), or 
may be cured (c). If not, they face a time-dependent probabiity of 
cancer death P(r) (see Appendix). All patients ran a risk of dying from 
other causes and a kigher risk of a second primary tumour. 
colorectal cancer for the not cured is lognormally distributed 
over time, character&d by a geometric mean (identical to 
the median survival time) and variance (see Appendix) [20]. 
Consequently, the model accommodates changes in four compo- 
nents of prognosis: the probability of surviving primary treat- 
ment, the probability of being cured and, if not cured, the 
median survival time and variance before dying from colorectal 
cancer. The CFR, defined as the fraction that dies in hospital 
within 2 months of primary diagnosis, is known from the 
hospital register. The fraction which is cured approximates the 
fraction surviving 10 years after hospital discharge (corrected 
for death from other causes): the risk of dying more than 10 
years after diagnosis of colorectal cancer equals the risk of death 
of the reference population [21]. All patients, the cured and the 
not cured, run twice the risk of the reference population for a 
second primary colorectal cancer [22]. All persons, healthy, 
cured and not cured, run a risk of dying from all other causes, 
determined by Dutch life tables corrected for colorectal cancer 
death [12]. 
The survival distribution is first estimated by an iterative non- 
linear least squares regression, weighted for the numbers of 
death, based on survival figures from the Norwegian and SE-N 
cancer egistry [23,24]. Then, by using incidence and survival, 
the model determines expected mortality: the model starts from 
observed incidence and calculates expected numbers of death, 
given a stated survival and cure rate. Combinations of cure 
rates and survival periods will lead to age-specific estimates of 
mortality, which may or may not be different from observed 
estimates (see Appendix). Numerous pairs of cure rates and 
survival periods have been tested. The variance between calcu- 
lated and observed numbers of deaths is tested by assuming a 
Poisson distribution of the probability of death (see Appendix) 
[25]. If the calculated numbers differ significantly from the 
observed (P < O.OS), that speciiic pair of cure rate and survival 
period is rejected as unlikely. 
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RESULTS 
For both sexes, rates of first admissions increased over the 
period 1978-1989, while mortality remained stable or declined 
(Figure 1). The cancer incidence and mortality of the Southeast- 
ern Netherlands howed the same trend, although the incidence 
mortality ratios were somewhat higher (Table 1). The cancer 
incidence of 1989 corresponded closely with the first admission 
rates of the hospital register of the same year (Figure 1). 
Table 2 shows the annual changes by age and sex, estimated 
by the loglinear age-period models. Over this relatively short 
period, first admission rates increased by 39.9% (Males) and 
20.4% (Females), rates of major interventions after primary 
diagnosis increased by 32.6% (Males) and 14.0% (Females), but 
mortality nearly remained stable for men (+ 2.2%) and declined 
substantially among women (- 15.3%). Hence, clinical inci- 
dence increased by more than 35% relative to mortality, and the 
incidence of major interventions increased by 30%. The standard 
errors (SE) in Table 1 show that this increase in clinical 
incidence compared with mortality is highly significant. Major 
intervention rates during primary admission increased 5% less 
steeply than first admission rates: this difference is statistically 
not significant, but probably indicates a shift from major surgery 
towards more non-invasive colonoscopic treatment for early 
lesions. 
The CFR in these age groups declined quite strongly: from 
5.6% (SE 0.5) for men and 5.9% (SE 0.5) for women in 
1978-1980 to 2.5% (SE 0.3) and 2.4% (SE 0.3), respectively. 
However, as shown in Table 1, this decline in lethality can only 
explain the smaller part of the observed difference between the 
morbidity and mortality trend: late mortality, excluding deaths 
during first admission, increased by 9.2% among men and 
decreased among women (- 9.5%). 
Table 3 shows relative survival rates which fit closely the 
observed incidence and mortality rates of two 3 year periods at 
the beginning and at the end of the study period. Alongside 
these simulated relative survival rates are the figures from 
Scandinavian and Dutch cancer registries originally used for 
estimation of the survival distribution. The simulated (fitted) 
survival rates are slightly lower than the observed. This can be 
expected if the hospital register misses a few very early lesions 
with good prognosis, curable by non-invasive procedures (see 
Discussion). 
The relative survival expected for 1987-1989 predicts that 
cure rates (equal to the 10 year relative survival rate after hospital 
discharge) have increased by 11.8%, given a constant median 
survival time: from 41.8% (range 38.W.5) in 19711980 to 
53.6% (range 51.2-55.1) in 1987-1989. In otherwords, for every 
100 patients (< 65 years old) admitted in 1978-1980,6 died in 
hospital and 55 in the subsequent years; 9 years later less than 3 
died in hospital and 45 will die in subsequent years. 13 extra 
patients survived a colorectal cancer diagnosis, 3 thanks to 
lowered hospital mortality. 
Figure 3 shows areas of all pairs of cure rates and median 
survival time which fit the observed incidence and mortality 
within 95% confidence limits (see Appendix). As median survival 
increases, the corresponding cure rate has to decrease to fit the 
given mortality. Indeed, two processes can explain any change 
in mortality rates, given incidence: death from colorectal cancer 
can be cancelled (hence, persons are cured; arrow a in Figure 3) 
or postponed (hence, median survival is increased; arrow b in 
Figure 3). Obviously, both processes can also take place at the 
same time (arrow c in Figure 3). For example, the incidence and 
mortality data of 19711980 can be explained by a median 
survival of 1.5 years and a cure rate of 0.44 or by a median 
Table 2. Annual change of admissions, major interventions and deaths by age and sex over the 
period 1978-1989; “late deaths” refers to all patients dying after surviving primary diagnosis and 
treatment, and corrects for changes in operative lethality 
Men; % annual change (standard errors in parentheses) 









0.0 (1.9) -2.2 (2.2) -5.5 (3.1) -4.7 (3.2) 
0.2 (1.5) -0.4 (1.7) -3.1 (2.3) -2.4 (2.4) 
5.9 (1.5) 4.2 (1.2) 0.5 (1.7) 0.7 (1.8) 
3.1 (0.9) 2.4 (0.9) -0.8 (1.3) -0.4 (1.4) 
3.3 (0.7) 2.4 (0.7) 1.2 (1.0) 1.9 (1.0) 
3.4 (0.6) 3.0 (0.6) 0.0 (0.8) -0.5 (1.1) 
2.8 (0.5) 2.6 (0.5) 0.7 (0.6) 1.3 (0.7) 
3.1 (0.3) 2.6 (0.3) 0.2 (0.4) 0.8 (0.4) 
Women; % annual change (standard errors in parentheses) 









2.6 (2.1) 3.2 (2.4) -0.3 (3.7) -0.6 (3.8) 
-0.2 (1.6) 1.4 (4.2) -2.2 (2.5) -1.8 (2.6) 
0.1 (1.2) -0.1 (1.2) -2.6 (1.8) -2.4 (1.8) 
2.2 (0.9) 1.0 (1.0) -1.9(1.4) -0.9 (1.4) 
2.0 (0.7) 1.1 (0.7) -1.3 (1.0) -0.5 (1.1) 
1.1 (0.6) 1.0 (0.6) -1.5 (0.8) -1.1 (0.8) 
2.2 (0.5) 1.6 (0.5) -1.4(0.7) -0.7 (0.7) 
1.7 (0.3) 1.2 (0.3) -1.5 (0.4) -0.9 (0.4) 
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Table 3. Published relative survival rates in % from Scandinavian wuntries [23, 26, 271 and The Southeastern 
Netherlands (SE-N) [24] are compated with the simulated relative survival, whichfits best observedfirst admission 
and mortality rates from the periods mentioned 
Observed Simulated 
Finland Norway Sweden Sweden SE-N The Netherlands 
Time after diagnosis 1953-1974 1972-1975 1970-1974 1975-1979 1975-1985 1978-1980 1987-1989 
2 months NA NA 88.6 90.6 NA 94.2 97.5 
lY=r 54.2 67.1 70.5 71.7 NA 68.0 74.3 
3 years NA 47.8 NA NA NA 48.2 58.8 
5 years 31.1 42.7 45.0 46.8 46.5 42.6 54.6 
10 years 30.2 NA 41.9 NA 42.2 39.4 52.3 
NA, not available in published ligures. 
0.60 
0.30 L I I I 
1.0 1.5 2.0 2.5 3.0 
Median survival time (years) 
Figure 3. Two way sensitivity analysis. The two areas contain all 
pairs of cure rate and median survival of the not cured which will fit 
the given incidence and mortality rates of 19784980 and 1987-1989 
within 95% confidence limits. The arrows indicate three hypothetical 
explanations for the difference between the two periods: increase of 
numbers which are cured (a), increase of survival of the not cured (b), 
or a combination of both (c). 
survival of 3 years and a cure rate of 0.37. The incidence and 
mortality figures of 1987-1989 can be explained by a median 
survival of 1.5 years and a cu:re rate of 0.54 or a median survival 
of 3 years and a cure rate of 0.50. Figure 3 shows also that the 
model is much less sensitive to changes in assumptions about the 
median survival time than cure rate. To fit the same combi- 
nations of incidence and mortality, cure rates have to decrease 
by an average of 4.2% (a relative decrease of 10%) when median 
survival increases within 1 year (a relative increase of more than 
50%). This is a consequence of the fact that more than 80% of 
those who will eventually die of colorectal cancer will do so 
within 3 years of their diagnosis. Consequently, prolonged 
survival in the absence of cure cannot explain much of the 
widening gap between incidence and mortality; cure rates must 
have improved considerably. The most plausible explanation for 
the increasing cure rates is increasing case detection. Earlier 
diagnosis probably improves, the effectiveness of treatment [9] 
and certainly increases the numbers of benign lesions. 
DISCUSSION 
The first question to be addressed concerns the validity of the 
data. We found increasing clinical incidence and decreasing 
mortality. For the considered age groups, colorectal cancer 
mortality trends are generally valid [3]. Artefactual trends may 
be caused by higher diagnostic efficacy in more recent periods; 
fewer fatal cancers are missed and more patients with widespread 
cancer have the site of primary origin of their cancer determined. 
However, these changes in diagnostic practice will increase, not 
lower disease-specific mortality. 
Incidence data are collected from the hospital register, which 
is not constructed for epidemiological purposes. Less than 3% 
of young and middle aged patients with a primary diagnosis of 
colorectal cancer will not be treated, thus hospitalisation rates for 
incident colorectal cancer are nearly complete [181. If anything, 
patients with early lesions curable by non-invasive colonoscopic 
procedures tend to be treated more often in outpatient clinics, 
which will cause an artefactual decreasing trend of admission 
instead of increasing. Only substantial changes in codification 
practices of both admissions for colorectal cancer and of major 
interventions might have biased trend estimates; we cannot 
exclude a priori such changes, but they seem unlikely for such a 
short period and for a disease such as colorectal cancer. Finally, 
the Dutch hospital register shows the same trends as those 
observed in the regional cancer register in the Southeastern 
Netherlands (Table 1 and Figure 1); similar analyses will yield 
similar results. Regional differences do exist, but nevertheless 
are small. The Netherlands are small, with a homogeneous 
population. 
Our analysis might be weakened by the cross-sectional nature 
of the incidence and mortality data, biasing our assessment of 
(longitudinal) changes in prognosis. However, the effects of 
therapy are period-, not cohort-dependent and most deaths from 
colorectal cancer occur within 3 years of primary diagnosis 
(Table 3). The most recent mortality figures (199&1992) suggest 
a sharpening decrease, particularly among men [ 121. This would 
be inconsistent with the hypothesis that death is only postponed, 
not cancelled; such postponed eaths would cause a “catch-up” 
increase of mortality. 
Increasing incidence and decreasing mortality of colorectal 
cancer can only be explained by a substantial improvement in 
prognosis. We have quantified the expected increase in survival 
needed: cure rates, defined as 10 year survival after hospital 
discharge, have to increase by 12% between 1978-1980 and 
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1987-1989, from 42 to 54%. The simulated survival distribution 
for the beginning of the period (1978-1980) was similar to the 
observed figures of cancer registries. The mortality soon after 
primary diagnosis decreased, as has been observed elsewhere 
[26, 281. This can be attributed, at least partly, to increases in 
therapeutic efficacy, safer intervention procedures and better 
postoperative care [28]. However, as shown in Table 2, this 
change can only explain the smaller part of the observed diver- 
gence between morbidity and mortality. Recent advances have 
been made in the adjuvant treatment of advanced colorectal 
cancer, but such treatments were rarely applied before 1990 in 
The Netherlands [5, 6, 291. We did not find any other indication 
of advances in treatment which might have benefited more 
than a small subgroup (such as patients with solitary hepatic 
metastases), except for the short-term results of surgery. Conse- 
quently, the statement hat the divergence between incidence 
and mortality trends has been caused by improved therapy and 
decreasing lethality is not well supported. 
If we exclude less likely alternative hypotheses, such as 
decreasing malignancy of colorectal cancer in humans, the 
most probable explanation of the improving prognosis remains 
increased case detection. Earlier diagnosis deals with both 
incidence and mortality simultaneously: 
1. Earlier diagnosis may account for decreasing lethality. While 
this remains a matter for debate, there is now at least some 
evidence that earlier diagnosis improves long term prognosis [9]. 
2. Earlier diagnosis will increase incidence by shifting diagnosis 
towards an earlier age. In screening theory this is called lead 
time [7, 301. Obviously, lead time alone would not cause an 
incidence increase: a tumour which is diagnosed at the earlier 
age, (a - t), will not be diagnosed again at age (a). But, in period 
(a - t), patients run a risk of dying of other causes and colorectal 
cancer incidence increases sharply with age. The steeper the 
incidence increases with age, the more lead time will increase 
observed incidence rates, by moving diagnosis to younger ages. 
For colorectal cancer, shifting the whole age-specific incidence 
curve of 19711980 by 1 year towards a younger age causes an 
increase of the age standardised incidence by 12.5%. 
However, advancing diagnosis by 1 year in the natural disease 
progression will cause a shift of incidence by age which is always 
more than 1 year. This is caused by “length time bias”-the 
slower tumours grow, the likelier they are to be detected by 
earlier diagnosis [7, 301. How much incidence will increase, 
given earlier diagnosis, depends again on the relation of incidence 
with age and of the time distribution of the “silent” period that 
tumours would have passed unnoticed previously, but are 
detected now. This distribution is unknown, but will reflect the 
variability of disease progression. A high variability implies 
many slowly growing tumours and a high potential to boost 
observed incidence. Such high variability seems likely; unsus- 
pected macroscopic olorectal cancer during necropsy varies 
between 1 and 1.7% in occidental countries, representing nearly 
20% of all incident colorectal cancers [31, 321. Without early 
detection, many of those ‘slow growers’ will remain unnoticed 
because the person will have died before, from other causes. 
We conclude that the increase in incidence of colorectal cancer 
and the concomitant decrease in mortality cannot be caused by 
therapeutic improvements only. The most probable explanation 
of this divergence is increased cancer detection. This has 
important epidemiological nd health policy implications: 
(i) Increasing case-detection, which shifts cancer diagnosis to an 
earlier age both of the patient and the tumour, increases inci- 
dence (at least in age-dependent cancers) and decreases mortality 
simultaneously, biasing both as indicators of underlying cancer 
hazards. Time series of stage at primary diagnosis might confirm 
this; in the U.S.A., where incidence and mortality diverge 
similarly, more early lesions are detected, while rates of distant 
disease remain stable [33]. However, to evade stage migration 
bias, stages should be ascertained independently of modern 
imaging techniques. 
(ii) No recommended screening policy, or even proof of benefit, 
was needed to increase case detection, and induce a parallel 
increase in major interventions. It is worrying that we do not 
know how much of the induced morbidity increase is truly 
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APIPENDM 
Survival was modelled by u:sing a discrete approximation of the 
lognormal distribution, with median survival p, variance d and ti the i- 
th month after diagnosis. The probability of surviving colorectal cancer 
until time @‘(.I$, is then given by: 
P&h, = (1 - CFRJ 
i 
c, + (1 - CA py 
The subscript a refers to two age groups (< 55 and 55-64 years); these 
age groups have been introduced because younger persons had a lower 
CFR and a higher cure rate, resulting in a better survival. CFR is the 
fraction of persons, tirst admitted for colorectal cancer, dying in hospital 
within 2 months, and c (for “cured”) is the fraction of long-term (10 
year) survivors. Models incorporating sex as a determinant for survival 
were not signilicantly better, and were ignored. c, p and cr are estimated 
from observed survival figures, and then varied by the model (see 
further). 
The presented cancer model is a subsector of a global public health 
model, mode&g several diseases, and is implemented as a continuous 
time Markov chain, describing discrete sub-populations, cycling in 1 
year steps. The continuous time specification allows multiple transitions 
in one time step [34]. To this aim, the parsimonious lognormal distri- 
bution, defined by two parameters, is translated into a sequence of 
exponential waiting time distributions, described by four parameters, 
simulating the lognormal survival distribution in the Markov model. 
The subpopulation which survives mortality related to primary diag- 
nosis and therapy but which is not “cured”, enters a first stage. They 
will leave that stage with transition probability P and median duration 
-In (0.5)/P. After leaving this stage, parametery distributes urvivors 
over two subpopulations in two separate terminal stages, with transition 
probabilities 4 and r leading to death from colorectal cancer. For the 
purpose of this paper, these parameters have no direct practical meaning, 
except for simulating the lognormal survival distribution for a population 
of uncurable colorectal cancer patients. 
The mean (and median) survival of incurable patients is changed by 
the model through P. The variablesy , q and r are kept constant; changing 
these parameters has the same effect of prolonging the disease process. 
Random values between 0 and 1 are generated for the cure rate c and for 
the transition probability P, and the calculated number of colorectal 
cancer deaths are then compared to the observed numbers by the scaled 
deviance (log likelihood ratio statistic). Let O,,, be the observed number 
and E,,+ the expected calculated by the model, with a reference to all 5 
year age groups between 30 and 64 and s to sex, then the scaled deviance 
A [25] is calculated by 
- E,,,) 1 
If the calculated numbers differ significantly (P < 0.05), the pair of c 
and P values is rejected as unlikely. 
